Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Ratio (2016 - 2026)

Ocular Therapeutix has reported Equity Ratio over the past 14 years, most recently at 0.79 for Q1 2026.

  • For Q1 2026, Equity Ratio rose 21.19% year-over-year to 0.79; the TTM value through Mar 2026 reached 0.79, up 21.19%, while the annual FY2025 figure was 0.81, 17.59% up from the prior year.
  • Equity Ratio for Q1 2026 was 0.79 at Ocular Therapeutix, down from 0.81 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.81 in Q4 2025 and troughed at 0.03 in Q2 2023.
  • A 5-year average of 0.49 and a median of 0.63 in 2025 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: crashed 93.38% in 2023 and later skyrocketed 2799.88% in 2024.
  • Year by year, Equity Ratio stood at 0.24 in 2022, then soared by 52.56% to 0.36 in 2023, then skyrocketed by 90.47% to 0.69 in 2024, then rose by 17.59% to 0.81 in 2025, then fell by 1.95% to 0.79 in 2026.
  • Business Quant data shows Equity Ratio for OCUL at 0.79 in Q1 2026, 0.81 in Q4 2025, and 0.63 in Q3 2025.